# Macupatide Beginner's Guide: Lilly's LY3532226 Pipeline Peptide
> Note: PeptIQ is not a medical provider. Macupatide is investigational. Educational content only.
Macupatide (LY3532226) shows up in ClinicalTrials.gov clusters alone or with eloralintide (LY3841136) for obesity / overweight / type 2 diabetes populations. It does not yet have the same public Phase 2 megaphone as eloralintide — which is exactly why beginners invent dosing folklore.
Beginner Rules
- Code name literacy first — LY3532226 ≠ LY3841136
- No copy-paste doses — do not apply eloralintide's 1–9 mg map to macupatide
- Combo trials ≠ DIY stacks — registry arms are not syringe recipes
- Evidence tier — early pipeline signal until peer-reviewed dose tables publish
Why Lilly Would Study It
Lilly's metabolic portfolio already spans tirzepatide, retatrutide, orforglipron, and eloralintide. Macupatide extends the option set for monotherapy and combination experiments — the same strategic pattern as Novo running both CagriSema and amycretin.
What to Watch
- Peer-reviewed dose-response tables
- Monotherapy vs eloralintide-combo readouts
- Tolerability and discontinuation rates
- How it is positioned vs amylin-selective eloralintide
FAQ
Q: Is macupatide an amylin drug?
A: Treat public framing carefully; confirm mechanism from primary sources as publications land. Do not assume identity with eloralintide.
Q: Can I buy macupatide?
A: Not as a responsible consumer protocol today. Stay in clinical channels.
Bottom Line
Macupatide is the Lilly pipeline name to file next to eloralintide — learn the code, refuse fake charts, wait for dose tables.
Download PeptIQ to keep multi-agent metabolic watchlists organized.
Educational content only. Not medical advice.
